Table 3. Relationship Between Hepatitis B Core Antibody and Clinical and Laboratory Parameters in Hemodialysis Patients With (Group 1) or Without (Group 2) Hepatitis C Virus Infection.

	Group 1 (n = 79)			Group 2 (n = 66)			P value
	Anti-HBc Positive (n = 20)	Anti-HBc Negative (n = 59)	P value	Anti-HBc Positive (n = 9)	Anti-HBC Negative (n = 57)	P value
Age, y, mean ± SD	46.6 ± 10.6	45.8 ± 10.3	0.7	47.3 ± 8.3	46.8 ± 10.3	0.8	0.9
Sex, No (%)			0.1			0.4	0.1
Male	7 (35)	35 (59.3)		4 (44.4)	36 (63.1)
Female	13 (65)	24 (40.6)		5 (55.5)	21 (36.8)
Duration of hemodialysis, mo, mean ± SD	35.7 ± 10.4	28.7 ± 10.7	0.05	32.2 ± 11	30.7 ± 10.07	0.6	0.03
Positive history of transfusion, No. (%)	20 (100)	50 (84.7)	0.02	9 (100)	46 (80.7)	0.07	0.01
Positive schistosoma antibodies, No. (%)	16 (80)	35 (59.3)	0.04	5 (55.5)	31 (54.3)	0.4	0.01
AST, IU/L, mean ± SD	29 ± 7	27 ± 13	0.4	28 ± 6	26 ± 12	0.4	0.6
ALT, IU/L, mean ± SD	30 ± 11	26 ± 18	0.3	30 ± 11	26 ± 18	0.5	0.7
Albumin, g/dL, mean ± SD	3.6 ± 0.4	3.7 ± 0.1	0.4	3.5 ± 0.5	3.6 ± 0.3	0.4	0.6
Bilirubin, mean ± SD	1.3 ± 0.5	1.2 ± 0.4	0.3	1.5 ± 0.6	1.4 ± 0.7	0.6	0.1
Anti-HBs (positive)	7 (35)	17 (28.8)	0.2	5 (55.5)	15 (26.3)	0.03	0.9
HBV DNA positive, No (%)	3 (15)	1 (1.6)	0.004	2 (22.2)	0	-	0.6